Clinical trial · Interventional
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
NCT07693452CI-TRIAL-00117697recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appendiceal Mucinous Neoplasm | Appendix Mucinous Neoplasm | ALIAS | 0.90 |
| Pseudomyxoma Peritonei | Pseudomyxoma Peritonei | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metformin Treatment
- description
- 850mg PO daily
- interventionNames
- Drug: Metformin
Primary outcomes (1)
- measure
- Proportion of Participants who have completed at least (≥) 80% of planned metformin doses by 6 months
- timeFrame
- 6 months
- description
- Examine the feasibility of metformin therapy in patients with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs)
Secondary outcomes (1)
- measure
- Progression Free Survival (PFS)
- timeFrame
- 6, 12 and 18 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria (complete details available in protocol): * Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC * Age ≥18 years * ECOG performance status ≤2 Key Exclusion Criteria (complete details available in protocol): * Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC * Patients currently taking metformin for another medical indication * Patients with a prior adverse event to administration of metformin
References
Publications (0)
Data not yet available
No reference posted for this study.